<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Choice of progestin therapy for treatment of endometrial hyperplasia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Choice of progestin therapy for treatment of endometrial hyperplasia</h1>
<div class="graphic"><div class="figure"><div class="ttl">Choice of progestin therapy for treatment of endometrial hyperplasia</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="25%"></colgroup><colgroup width="15%"></colgroup><colgroup width="35%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug*</td> <td class="subtitle1">Treatment dose<br/> (typically used for 3 to 6 months at which point endometrial sampling is repeated) </td> <td class="subtitle1">Provides contraception</td> <td class="subtitle1">Patient selection</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Preferred:</td> </tr> <tr class="divider_bottom"> <td class="indent1">Levonorgestrel 52 mg IUD (LNG 52; Mirena, Liletta)<sup>¶,Δ</sup></td> <td>Releases 20 mcg/day initially</td> <td>Yes</td> <td>The LNG 52 is the <strong>preferred</strong> progestin therapy for pre- and postmenopausal patients with EH (any type)</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Alternatives for patients who decline, or cannot tolerate, the LNG 52:</td> </tr> <tr> <td class="indent1">Megestrol acetate</td> <td>40 to 160 mg orally daily<sup>◊,§</sup></td> <td>No</td> <td>Can be used for pre- and postmenopausal patients with EH (any type)</td> </tr> <tr> <td class="indent1">Medroxyprogesterone acetate (MPA)</td> <td>10 to 20 mg orally daily<sup>§</sup></td> <td>No</td> <td>Can be used for pre- and postmenopausal patients with EH (any type)</td> </tr> <tr> <td class="indent1">Norethindrone acetate (NETA, also known as norethisterone acetate; Aygestin)</td> <td>5 to 15 mg orally daily</td> <td>No</td> <td>Can be used for pre- and postmenopausal patients with EH (any type) who decline, or cannot tolerate, stronger oral progestins</td> </tr> <tr> <td class="indent1">Micronized progesterone (oral)</td> <td>200 to 300 mg orally daily</td> <td>No</td> <td>Use <strong>only</strong> for patients with <strong>all</strong> of the following: <ul class="decimal_heading"> <li>EH without atypia (any menopausal status), <strong>and</strong></li> <li>Who decline, or cannot tolerate, stronger oral progestins</li> </ul> </td> </tr> <tr> <td class="indent1">Norethindrone (progestin-only contraceptive pill; eg, Camila, Ortho Micronor)</td> <td>0.35 mg orally twice or three times daily</td> <td>Yes<sup>¥</sup></td> <td>Use <strong>only</strong> for patients with <strong>all</strong> of the following: <ul class="decimal_heading"> <li>Premenopausal status, <strong>and</strong></li> <li>Require contraception</li> </ul> </td> </tr> <tr> <td class="indent1">Combined estrogen-progestin contraceptive (COC)</td> <td>Variable; refer to product labeling</td> <td>Yes</td> <td>Use <strong>only</strong> for patients with <strong>all</strong> of the following: <ul class="decimal_heading"> <li>Premenopausal status, <strong>and</strong></li> <li>EH without atypia, <strong>and</strong></li> <li>Require contraception</li> </ul> </td> </tr> <tr> <td class="indent1">Depo medroxyprogesterone acetate (DMPA)</td> <td>150 mg intramuscularly every three months</td> <td>Yes</td> <td>Use <strong>only</strong> for patients with <strong>all</strong> of the following: <ul class="decimal_heading"> <li>Premenopausal status, <strong>and</strong></li> <li>EH without atypia, <strong>and</strong></li> <li>Who decline, or cannot tolerate, stronger oral progestins</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">For additional discussion, including choice of treatment and duration, refer to UpToDate content on management of endometrial hyperplasia and related algorithms.</div><div class="graphic_footnotes"><p>IUD: intrauterine device; LNG: levonorgestrel; EH: endometrial hyperplasia; FDA: United States Food and Drug Administration.<br/>* The medications listed are not approved by the FDA for treatment of endometrial hyperplasia. Megestrol acetate and depot medroxyprogesterone acetate are FDA-approved at higher doses for treatment of endometrial cancer.<br/>¶ LNG 52 is approved for six years of use as a contraceptive; however, as the dose rate decreases to approximately 10 mcg per day at 5 years, we remove and replace the IUD at five years when treating EH.<br/>Δ Lower dose LNG-releasing IUDs are also available (ie, LNG 19.5, LNG 13.5); however, these have not been studied in patients with EH and, in our practice, we do not use them for treatment of EH.<br/><font class="lozenge">◊</font> May cause weight gain (acts as an appetite stimulant), particularly at higher doses. Dose selection is based on shared decision-making and tolerance of side effects. One contributor's practice is to use 40 mg twice daily for patients with EH without atypia and 80 mg twice daily for patients with EH with atypia.<br/>§ Higher doses have been reported.<br/>¥ Progestin-only pills have lower contraceptive efficacy than IUDs or combined estrogen-progestin contraceptives; they must be taken at the same time each day to maximize contraceptive efficacy.</p></div><div class="graphic_reference">References:

	<ol>
<li>American College of Obstetricians and Gynecologists. Endometrial intraepithelial neoplasia. Committee Opinion No. 631. Obstet Gynecol 2015; 125:1272.</li>
<li>Wang Y, Nisenblat V, Tao L, et al. Combined estrogen-progestin pill is a safe and effective option for endometrial hyperplasia without atypia: a three-year single center experience. J Gynecol Oncol 2019; 30:e49.</li>
<li>Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 1997; 90:434.</li>
<li>Orbo A, Vereide A, Arnes M, et al. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial. BJOG 2014; 121:477.</li>
<li>Marra C, Penati C, Ferrari L, et al. Treatment of simple and complex endometrial non-atypical hyperplasia with natural progesterone: response rate to different doses. Gynecol Endocrinol 2014; 30:899.</li>
<li>Nooh AM, Abdeldayem HM, Girbash EF, et al. Depo-Provera versus norethisterone acetate in management of endometrial hyperplasia without atypia. Reprod Sci 2016; 23:448.</li>
<li>Gallos ID, Shehmar M, Thangaratinam S, et al. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 2010;203:547.e1.</li>
</ol></div><div id="graphicVersion">Graphic 115020 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
